Designing an Indicator‑Driven, Value‑Based Architecture for Pneumonia Prevention in Japan: A Formative Policy Viewpoint on Adult Vaccination and Oral Care Japan's aging society concentrates pneumonia burden across communities, long‑term care, perioperative pathways, and hospitals. Adult pneumococcal and influenza vaccination are supported by trials and meta‑analyses and are often cost‑effective; yet, realized value depends on targeting, measurement, financing, and pairing with bedside prevention such as oral care and hospital‑acquired pneumonia bundles. This viewpoint proposes a formative, indicator‑driven architecture linking cost‑effectiveness to operations by aligning vaccination with complementary oral‑care prevention and value‑based payment under the existing policy infrastructure. Working within the Ministry of Health, Labour and Welfare/Central Social Insurance Medical Council health technology assessment framework, Center for Outcomes Research and Economic Evaluation for Health methods, and claims–electronic health record linkage via My Number insurance card, we specify a compact national indicator set: vaccination coverage and timeliness, nonventilator hospital‑acquired pneumonia, ventilator‑associated pneumonia, postoperative and stroke‑associated pneumonia, antibiotic days of therapy, and length of stay, with pragmatic risk adjustment and present‑on‑admission flags. Value levers first reward reliable reporting and adherence to evidence‑based bundles and then share verified, risk‑adjusted savings. Long‑term care facilities receive add‑ons for professional oral care in high‑risk residents; hospitals receive quality add‑ons and shared savings; perioperative pathways may incorporate oral health management; and stroke units standardize oral hygiene with dysphagia screening. A phased roadmap details the pilot co‑design, governance, risk‑adjusted reporting with equity safeguards, and iterative recalibration by using real‑world evidence. The learning loop—measure, report, improve, generate evidence, adapt cost‑effectiveness, recalibrate payment—converts modeled value into lived experience: fewer pneumonias, reduced antibiotic exposure, shorter stays, improved function, and dignity at favorable or potentially lower costs, context-depending on baseline pneumonia rates, implementation fidelity, and local unit costs.

JMIR Formative Res: Designing an Indicator‑Driven, Value‑Based Architecture for Pneumonia Prevention in Japan: A Formative Policy Viewpoint on Adult Vaccination and Oral Care #PneumoniaPrevention #AdultVaccination #ValueBasedCare #HealthPolicy #JapanHealthcare

Toward Harmonized Adult Vaccination Schedules Across Canada: Consensus Statement and Recommendations | January 2026 | International Federation on Ageing, Vaccines4Life | www.vaccines4life.com/wp-co... #AdultVaccination #VaccinesSaveLives #VaccinesWork #GetImmunized

🌍 𝗢𝗻𝗲 𝗛𝗲𝗮𝗹𝘁𝗵 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗼𝘂𝗻𝗱𝘂𝗽: 𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 & 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀

Check out our first digest of 2026!

🔗 : onehealthtrust.org/news-media/w...

#antimicrobialresistance #amr #pakistan #h5n1 #adultvaccination #foodanimals #dataintoaction #onehealth #onehealthmonth

US Panel Stops Recommending COVID-19 Vaccine for All Adults US Vaccine Advisory Panel No Longer Recommends COVID-19 Vaccines for All Adults Published Time: 09-20-2025, 12:00 EDT The Advisory Committee

ACIP Panel No Longer Recommends COVID-19 Vaccine for All US Adults

#COVID19Vaccine #ACIPUpdate #USVaccinePolicy #AdultVaccination #CDCLeadership

A key theme: Is the HPV vaccine beneficial for older individuals or those with prior exposure? Many argue adults can still benefit, as it protects against strains they may not have encountered yet. #AdultVaccination 6/7

In the ER, a Hidden Crisis in Adult Vaccination All the science news you can handle in a single feed

In the ER, a Hidden Crisis in Adult Vaccination #Science #HealthandMedicine #PublicHealth #AdultVaccination #PublicHealthCrisis #EmergencyRoomInsights